Puma Biotechnology | PBYI - Assets


Puma Biotechnology reported $202.86M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Moderna USD 10.96B 527M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026